Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism

Journal of Biological Chemistry

Volumn 287, Issue 28, 2012, Pages 23517-23526

  Mieczkowska, Aleksandra ^a,b   Baslé, Michel F ^b   Chappard, Daniel ^b   Mabilleau, Guillaume ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EFFECT; BONE FRACTURE; G PROTEIN COUPLED RECEPTORS; MOLECULAR MECHANISM; OSTEOCYTES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; SCLEROSTIN; SIGNALING PATHWAYS; THIAZOLIDINEDIONES; TYPE 2 DIABETES MELLITUS; UP-REGULATION;

CHEMICAL ACTIVATION; FRACTURE; PATIENT TREATMENT; PIGMENTS;

CELL DEATH;

G PROTEIN COUPLED RECEPTOR 40; GLITAZONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SCLEROSTIN; SYNAPTOPHYSIN; TROGLITAZONE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALVARIA; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; IMMUNOBLOTTING; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE; CELLS, CULTURED; FEMALE; GLYCOPROTEINS; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OSTEOBLASTS; OSTEOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PPAR GAMMA; RAS PROTEINS; REACTIVE OXYGEN SPECIES; RECEPTORS, G-PROTEIN-COUPLED; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 84863609091     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.324814     Document Type: Article

References (42)

1. Kawai, M., and Rosen, C. J. (2010) PPARγ: a circadian transcription factor in adipogenesis and osteogenesis. Nat. Rev. Endocrinol. 6, 629-636
2. Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., and Viberti, G. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427-2443 (Pubitemid 44903747)
3. Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., Standl, E., Wilcox, R. G., Wilhelmsen, L., Betteridge, J., Birkeland, K., Golay, A., Heine, R. J., Korányi, L., Laakso, M., Mokán, M., Norkus, A., Pirags, V., Podar, T., Scheen, A., Scherbaum, W., Schernthaner, G., Schmitz, O., Skrha, J., Smith, U., Taton, J., and PROactive investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366, 1279-1289 (Pubitemid 41416583)
4. Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., and Viberti, G. (2008) Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31, 845-851
5. Meymeh, R. H., and Wooltorton, E. (2007) Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ 177, 723-724 (Pubitemid 47523552)
6. Lecka-Czernik, B., Gubrij, I., Moerman, E. J., Kajkenova, O., Lipschitz, D. A., Manolagas, S. C., and Jilka, R. L. (1999) Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. J. Cell. Biochem. 74, 357-371 (Pubitemid 29344887)
7. Lecka-Czernik, B., Moerman, E. J., Grant, D. F., Lehmann, J. M., Manolagas, S. C., and Jilka, R. L. (2002) Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143, 2376-2384 (Pubitemid 34521584)
8. Berberoglu, Z., Gursoy, A., Bayraktar, N., Yazici, A. C., Bascil Tutuncu, N., and Guvener Demirag, N. (2007) Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J. Clin. Endocrinol. Metab. 92, 3523-3530 (Pubitemid 47435330)
9. Glintborg, D., Andersen, M., Hagen, C., Heickendorff, L., and Hermann, A. P. (2008) Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 93, 1696-1701 (Pubitemid 351656507)
10. Grey, A., Bolland, M., Gamble, G., Wattie, D., Horne, A., Davidson, J., and Reid, I. R. (2007) The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 92, 1305-1310 (Pubitemid 46556402)
11. Jennermann, C., Triantafillou, J., Cowan, D., Pennink, B., Connolly, K., and Morris, D. (1995) Effects of thiazolidinediones on bone turnover in the rat. J. Bone Miner. Res. 10, S241
12. Rzonca, S. O., Suva, L. J., Gaddy, D., Montague, D. C., and Lecka-Czernik, B. (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145, 401-406 (Pubitemid 38094536)
13. Bonewald, L. F. (2008) in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (Rosen, C. J., ed) pp. 22-27, 7th Ed., American Society for Bone and Mineral Research, Washington, D.C.
14. Plotkin, L. I., Aguirre, J. I., Kousteni, S., Manolagas, S. C., and Bellido, T. (2005) Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J. Biol. Chem. 280, 7317-7325 (Pubitemid 40341290)
15. Plotkin, L. I., Lezcano, V., Thostenson, J., Weinstein, R. S., Manolagas, S. C., and Bellido, T. (2008) Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J. Bone Miner. Res. 23, 1712-1721
16. Zhao, S., Zhang, Y. K., Harris, S., Ahuja, S. S., and Bonewald, L. F. (2002) MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J. Bone Miner. Res. 17, 2068-2079 (Pubitemid 35239208)
17. Mabilleau, G., Mieczkowska, A., and Edmonds, M. E. (2010) Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression. Diabet. Med. 27, 925-932
18. Smith, N. J., Stoddart, L. A., Devine, N. M., Jenkins, L., and Milligan, G. (2009) The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. J. Biol. Chem. 284, 17527-17539
19. 35S]thio)triphosphate binding studies reflects binding of an endogenous agonist. Mol. Pharmacol. 71, 994-1005
20. Alquier, T., Peyot, M. L., Latour, M. G., Kebede, M., Sorensen, C. M., Gesta, S., Ronald Kahn, C., Smith, R. D., Jetton, T. L., Metz, T. O., Prentki, M., and Poitout, V. (2009) Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 58, 2607-2615
21. Latour, M. G., Alquier, T., Oseid, E., Tremblay, C., Jetton, T. L., Luo, J., Lin, D. C., and Poitout, V. (2007) GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 56, 1087-1094 (Pubitemid 46525064)
22. Kato, Y., Windle, J. J., Koop, B. A., Mundy, G. R., and Bonewald, L. F. (1997) Establishment of an osteocyte-like cell line, MLO-Y4. J. Bone Miner. Res. 12, 2014-2023 (Pubitemid 27524478)
23. Dumas, A., Gaudin-Audrain, C., Mabilleau, G., Massin, P., Hubert, L., Baslé, M. F., and Chappard, D. (2006) The influence of processes for the purification of human bone allografts on the matrix surface and cytocompatibility. Biomaterials 27, 4204-4211
24. Takahashi, N., Udagawa, N., Tanaka, S., and Suda, T. (2003) Generating murine osteoclasts from bone marrow. Methods Mol. Med. 80, 129-144
25. Mabilleau, G., Chappard, D., and Sabokbar, A. (2011) Role of the A20-TRAF6 axis in lipopolysaccharide-mediated osteoclastogenesis. J. Biol. Chem. 286, 3242-3249
26. Mabilleau, G., Moreau, M. F., Filmon, R., Baslé, M. F., and Chappard, D. (2004) Biodegradability of poly(2-hydroxyethyl methacrylate) in the presence of the J774.2 macrophage cell line. Biomaterials 25, 5155-5162 (Pubitemid 38510401)
27. Mabilleau, G., Chappard, D., and Baslé, M. F. (2011) Cellular and molecular effects of thiazolidinediones on bone cells: a review. Int. J. Biochem. Mol. Biol. 2, 240-246
28. Luconi, M., Cantini, G., and Serio, M. (2010) Peroxisome proliferatoractivated receptor-γ (PPARγ): is the genomic activity the only answer? Steroids 75, 585-594
29. Colca, J. R., McDonald, W. G., Waldon, D. J., Leone, J. W., Lull, J. M., Bannow, C. A., Lund, E. T., and Mathews, W. R. (2004) Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am. J. Physiol. Endocrinol. Metab. 286, E252-E260 (Pubitemid 38140317)
30. Dewar, B. J., Gardner, O. S., Chen, C. S., Earp, H. S., Samet, J. M., and Graves, L. M. (2007) Capacitative calcium entry contributes to the differential transactivation of the epidermal growth factor receptor in response to thiazolidinediones. Mol. Pharmacol. 72, 1146-1156 (Pubitemid 350012589)
31. Fryer, L. G., Parbu-Patel, A., and Carling, D. (2002) The antidiabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 277, 25226-25232 (Pubitemid 34951829)
32. Gardner, O. S., Dewar, B. J., Earp, H. S., Samet, J. M., and Graves, L. M. (2003) Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. J. Biol. Chem. 278, 46261-46269 (Pubitemid 37452196)
33. Gardner, O. S., Dewar, B. J., and Graves, L. M. (2005) Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. Mol. Pharmacol. 68, 933-941 (Pubitemid 41345784)
34. 2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J. Biol. Chem. 276, 48950-48955
35. Gras, D., Chanez, P., Urbach, V., Vachier, I., Godard, P., and Bonnans, C. (2009) Thiazolidinediones induce proliferation of human bronchial epithelial cells through the GPR40 receptor. Am. J. Physiol. Lung Cell. Mol. Physiol. 296, L970-L978
36. Wu, P., Yang, L., and Shen, X. (2010) The relationship between GPR40 and lipotoxicity of the pancreatic β-cells as well as the effect of pioglitazone. Biochem. Biophys. Res. Commun. 403, 36-39
37. Cornish, J., MacGibbon, A., Lin, J. M., Watson, M., Callon, K. E., Tong, P. C., Dunford, J. E., van der Does, Y., Williams, G. A., Grey, A. B., Naot, D., and Reid, I. R. (2008) Modulation of osteoclastogenesis by fatty acids. Endocrinology 149, 5688-5695
38. Wan, Y., Chong, L. W., and Evans, R. M. (2007) PPARγ regulates osteoclastogenesis in mice. Nat. Med. 13, 1496-1503
39. Wei, W., Wang, X., Yang, M., Smith, L. C., Dechow, P. C., Sonoda, J., Evans, R. M., and Wan, Y. (2010) PGC1β mediates PPARγ activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab. 11, 503-516
40. Chan, B. Y., Gartland, A., Wilson, P. J., Buckley, K. A., Dillon, J. P., Fraser, W. D., and Gallagher, J. A. (2007) PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 40, 149-159 (Pubitemid 44839345)
41. Mbalaviele, G., Abu-Amer, Y., Meng, A., Jaiswal, R., Beck, S., Pittenger, M. F., Thiede, M. A., and Marshak, D. R. (2000) Activation of peroxisome proliferator-activated receptor-γ pathway inhibits osteoclast differentiation. J. Biol. Chem. 275, 14388-14393 (Pubitemid 30339723)
42. Okazaki, R., Toriumi, M., Fukumoto, S., Miyamoto, M., Fujita, T., Tanaka, K., and Takeuchi, Y. (1999) Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140, 5060-5065